KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments (2016 - 2026)

Biomarin Pharmaceutical has reported Other Gross PP&E Adjustments over the past 17 years, most recently at $2.1 billion for Q1 2026.

  • For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 5.75% year-over-year to $2.1 billion, compared with a TTM value of $2.1 billion through Mar 2026, up 5.75%, and an annual FY2025 reading of $2.0 billion, up 6.62% over the prior year.
  • Other Gross PP&E Adjustments came in at $2.1 billion for Q1 2026, up from $2.0 billion in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $2.1 billion in Q1 2026 to a low of $1.8 billion in Q1 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was $1.9 billion (2024), compared with a mean of $1.9 billion.
  • The sharpest move saw Other Gross PP&E Adjustments grew 9.18% in 2022, then fell 0.39% in 2025.
  • Over 5 years, Other Gross PP&E Adjustments stood at $1.8 billion in 2022, then grew by 1.19% to $1.8 billion in 2023, then increased by 1.18% to $1.9 billion in 2024, then grew by 6.62% to $2.0 billion in 2025, then grew by 3.29% to $2.1 billion in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Other Gross PP&E Adjustments are $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025).